Shopping Cart 0
Cart Subtotal
USD 0

Oryzon Genomics SA (ORY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Oryzon Genomics SA (Oryzon) is a clinical stage biopharmaceutical company that offers discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. The company offers epigenetics, a regulatory system that controls gene expression without affecting the makeup of the genes themselves and provides regulation of gene transcription that has emerged as a key biological determinant of protein production and cellular differentiation. Its clinical-stage product candidates include ORY-1001, an oncology product for treating acute leukemia disease; ORY-2001 for treating Alzheimer disease, Parkinson disease and others; and ORY-3001 for treating other indications of cancer. Oryzon provides therapeutic programs and collaborative research services. The company serves patients with cancers or neurodegenerative disorders. It operates office in Spain and the US. Oryzon is headquartered in Barcelona, Spain.

Oryzon Genomics SA (ORY)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oryzon Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oryzon Genomics SA, Medical Devices Deals, 2012 to YTD 2018 10

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deal Details 12

Equity Offering 12

Oryzon Genomics to Raise USD19.6 Million in Private Placement of Shares 12

Oryzon Genomics Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 14

Oryzon Genomics Raises Funds in IPO 15

Oryzon Genomics Raises USD19 Million in Private Placement of Shares 16

Oryzon Genomics SA-Key Competitors 17

Oryzon Genomics SA-Key Employees 18

Oryzon Genomics SA-Locations And Subsidiaries 19

Head Office 19

Other Locations & Subsidiaries 19

Joint Venture 19

Recent Developments 20

Financial Announcements 20

Jul 30, 2018: ORYZON reports financial results and corporate update for the 1st half ended June 30, 2018 20

May 09, 2018: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter 2018 22

Feb 19, 2018: ORYZON Reports Financial Results and Corporate Update for the 4th Quarter and Year Ended December 31, 2017 23

Nov 07, 2017: ORYZON Reports Financial Results and Corporate Update for the 3rd Quarter Ended September 30, 2017 25

Jul 28, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Half Ended June 30, 2017 27

May 09, 2017: ORYZON Reports Financial Results and Corporate Update for the 1st Quarter, 2017 29

Feb 24, 2017: ORYZON Reports Financial Results and Corporate Update for the Fourth Quarter and Year Ended December 31, 2016 31

Corporate Communications 32

Feb 19, 2018: Oryzon revamps its Board with an expert in Biomedicine and Epigenetics in the US industry 32

May 16, 2017: Oryzon announces appointment of new Chief Medical Officer and expansion of its Medical Department 33

Government and Public Interest 34

May 15, 2017: USD 2.6 Million in New Grants Spurs Innovation 34

Product News 37

05/30/2018: Oryzon Genomics reaffirms its commitment to the research in neurodegenerative diseases on the World Multiple Sclerosis Day 37

04/24/2017: ORYZON Announces New Grant from Alzheimer's Drug Discovery Foundation (ADDF) to develop a companion marker for its ORY-2001 epigenetic drug 38

02/05/2018: ORYZON Appoints Clinical Development Leader Lori A. Kunkel, M.D., as a Scientific Advisor 39

01/30/2017: Oryzon Genomics Will Present Data on ORY-1001 at Keystone Symposia on Epigenetics and Human Disease 40

01/30/2017: Oryzon Genomics Will Present ORY-2001 at Keystone Symposia on Epigenetics and Human Disease 41

01/29/2018: ORYZON announces First Patient In in ORY-2001 MS Phase IIA trial SATEEN and presents new data on ORY-2001 at the third annual ACTRIMS Forum 2018 in San Diego 42

Clinical Trials 43

Sep 10, 2018: ORYZON receives approval to start ALICE: a Phase II a clinical trial in AML with Iadademstat (ORY-1001) 43

Jun 25, 2018: ORYZON announces First Patients in the UK in ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY-2001 44

Jun 01, 2018: Oryzon to present at upcoming several international conferences 45

May 29, 2018: ORYZON Receives Approval in the United Kingdom to start ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY-2001 46

May 14, 2018: ORYZON announces First Patients In ETHERAL: a Phase IIa clinical trial in Alzheimers Disease with ORY-2001 47

May 08, 2018: ORYZON receives approval in France to start ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY- 2001 48

Apr 04, 2018: ORYZON receives approval to start ETHERAL: a Phase IIa clinical trial in Alzheimer's Disease with ORY-2001 49

Mar 05, 2018: ORYZON Announces Publication of Paper in Cancer Cell establishing the relevance of ORY-1001 as an antileukemic differentiating drug 50

Feb 21, 2018: Oryzon to present at upcoming international conferences 51

Jan 23, 2018: ORYZON to present at two US investor conferences 52

Jan 04, 2018: ORYZON to Present at the Neuroscience Innovation Forum in San Francisco 53

Dec 04, 2017: Preclinical Efficacy Data on Sickle Cell Disease of ORY-3001, a LSD1 inhibitor from ORYZON, to be presented at ASH 2017 54

Nov 13, 2017: ORYZON to present new preclinical data of ORY-2001 at the Neuroscience 2017 meeting organized by the Society for Neuroscience 55

Oct 31, 2017: ORYZON receives approval from AEMPS to start SATEEN: a Phase IIA clinical trial in Multiple Sclerosis with ORY-2001 56

Oct 09, 2017: ORYZON to present new data on its anti-neurodegenerative drug ORY-2001 at the International Conference on Multiple Sclerosis ECTRIMS-ACTRIMS 57

Jul 24, 2017: ORYZON presents final data on the Phase I trial with ORY-2001 at the Alzheimers Association International Conference (AAIC-2017) 58

Apr 03, 2017: ORYZON presents data on the Phase I trial with ORY-2001 at the 13th International Conference on Alzheimer's and Parkinson's diseases 59

Feb 27, 2017: ORYZON presented new preclinical data of ORY-2001 therapeutic activity in Multiple Sclerosis at ACTRIMS-2017 60

Feb 20, 2017: ORYZON to present ORY-2001 new preclinical data of therapeutic activity at ACTRIMS-2017 in Orlando, Fl. USA 62

Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer's and Parkinson's Diseases in Vienna, Austria 63

Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board 64

Jan 09, 2017: ORYZON Announces First Patient Dosed in Phase 1 Trial of the LSD1 inhibitor RG6016 in Small Cell Lung Cancer (SCLC) 65

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oryzon Genomics SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oryzon Genomics SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oryzon Genomics SA, Deals By Therapy Area, 2012 to YTD 2018 9

Oryzon Genomics SA, Medical Devices Deals, 2012 to YTD 2018 10

Oryzon Genomics SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Oryzon Genomics to Raise USD19.6 Million in Private Placement of Shares 12

Oryzon Genomics Raises USD0.7 Million in Private Placement of Shares upon Exercise of Warrants 14

Oryzon Genomics Raises Funds in IPO 15

Oryzon Genomics Raises USD19 Million in Private Placement of Shares 16

Oryzon Genomics SA, Key Competitors 17

Oryzon Genomics SA, Key Employees 18

Oryzon Genomics SA, Other Locations 19

Oryzon Genomics SA, Joint Venture 19

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Oryzon Genomics SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.